Icure Pharmaceutical Incorporation (KOSDAQ:175250)

KOSDAQ:175250 Revenue

Icure Pharmaceutical Incorporation had revenue of 22.13B KRW in the quarter ending March 31, 2025, with 38.86% growth. This brings the company's revenue in the last twelve months to 75.40B, up 32.03% year-over-year. In the year 2024, Icure Pharmaceutical Incorporation had annual revenue of 69.21B with 21.83% growth.

• Revenue (ttm): 75.40B
• Revenue Growth: +32.03%
• P/S Ratio: 0.97
• Revenue / Employee: 359.05M
• Employees: 210
• Market Cap: 73.13B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2024	69.21B	12.40B	21.83%
Dec 31, 2023	56.81B	-2.56B	-4.31%
Dec 31, 2022	59.37B	-4.92B	-7.65%
Dec 31, 2021	64.28B	-25.86B	-28.69%
Dec 31, 2020	90.14B	29.22B	47.97%